Shenzhen Chipscreen Biosciences Co. Ltd.SSE: 688321

Report for Q1 2026

· Issued by Shenzhen Chipscreen Biosciences Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · · 13 pages · Chinese

Summary by 6ix AI

The report highlights a substantial increase in revenue and net profit, driven primarily by sales growth of specific pharmaceutical products. The company also reported a notable rise in total assets and shareholders' equity, attributed to recent fundraising activities.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix

Earlier from Shenzhen Chipscreen Biosciences

Later from Shenzhen Chipscreen Biosciences

All Shenzhen Chipscreen Biosciences news releases